Skip to main content

Breadcrumb

  1. Home

Predicting pathological response after ipilimumab plus nivolumab in stage III urothelial cancer by liquid-biopsy assessment of plasma and urine ctDNA using the RaDaR assay

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Predicting pathological response after ipilimumab plus nivolumab in stage III urothelial cancer by liquid-biopsy assessment of plasma and urine ctDNA using the RaDaR assay

Plasma first: Accelerating lung cancer diagnosis through liquid biopsy

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Plasma first: Accelerating lung cancer diagnosis through liquid biopsy

Personalized circulating tumor DNA (ctDNA) analysis in patients with recurrent/metastatic head & neck squamous cell cancer (R/M HNSCC)

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Personalized circulating tumor DNA (ctDNA) analysis in patients with recurrent/metastatic head & neck squamous cell cancer (R/M HNSCC)

Liquid Biopsy for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS): A personalized cell-free tumor DNA analysis for patients with HNSCC

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Liquid Biopsy for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS): A personalized cell-free tumor DNA analysis for patients with HNSCC

Leveraging personalized circulating tumor DNA (ctDNA) for detection and monitoring of molecular residual disease in high-risk melanoma

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Leveraging personalized circulating tumor DNA (ctDNA) for detection and monitoring of molecular residual disease in high-risk melanoma

Preliminary results of the Liquid Biopsy for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS) study

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Preliminary results of the Liquid Biopsy for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS) study

PAK4 as a potential marker for poor response to immunotherapy in melanoma patients

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about PAK4 as a potential marker for poor response to immunotherapy in melanoma patients

Updated follow-up data and biomarker analysis of pre-operative ipilimumab and nivolumab in locoregional advanced urothelial cancer (NABUCCO)

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Updated follow-up data and biomarker analysis of pre-operative ipilimumab and nivolumab in locoregional advanced urothelial cancer (NABUCCO)

Liquid biopsy for detection of molecular residual disease and recurrence in head and neck squamous cell carcinoma

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Liquid biopsy for detection of molecular residual disease and recurrence in head and neck squamous cell carcinoma

A single-tube NGS assay for simultaneous detection of DNA and RNA biomarkers as a comprehensive solution for clinical management and guiding therapeutic intervention of Ph-like ALL patients

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about A single-tube NGS assay for simultaneous detection of DNA and RNA biomarkers as a comprehensive solution for clinical management and guiding therapeutic intervention of Ph-like ALL patients

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 63
  • Page 64
  • Page 65
  • Page 66
  • Page 67
  • Page 68
  • Page 69
  • Page 70
  • Page 71
  • …
  • Next page Next
  • Last page Last
Subscribe to